Skip to main content

Table 3 Prevalence and cumulative incidence of GI events

From: Gastrointestinal comorbidities associated with atrial fibrillation

Variable

All patients with AF (N = 557,123)

AF patients without history of GI at baseline (N = 413,168)

 

Number of GI casesa

Prevalence of GI (per 100 persons) [95% CIb]

Number of incident GI casesc

Cumulative incidence (per 100 persons) [95% CIb]

Any GI event

308,823

55.4 [55.3,55.6]

164,868

39.9 [39.8,40.1]

GI events based on the RE-LY study classificationd

215,942

38.8 [38.6,38.9]

108564

26.3 [26.1,26.4]

Dyspepsiae

164,892

29.6 [29.5,29.7]

79,069

19.1 [19.0,19.3]

Gastrointestinal bleeding

52,979

9.5 [9.4,9.6]

26,067

6.3 [6.2,6.4]

Vomiting

46,866

8.4 [8.3,8.5]

20,297

4.9 [4.8,5.0]

Diarrhea

43,628

7.8 [7.8,7.9]

19,928

4.8 [4.8,4.9]

Other GI events

    

Diverticula of intestine

62,638

11.2 [11.2,11.3]

30,983

7.5 [7.4,7.6]

Gastroesophageal reflux disease

63,159

11.3 [11.3,11.4]

28,938

7.0 [6.9,7.1]

Other disorders of intestine

49,736

8.9 [8.9,9.0]

23,435

5.7 [5.6,5.7]

Dysphagia

46,506

8.3 [8.3,8.4]

22,071

5.3 [5.3,5.4]

Gastritis and duodenitis

46,974

8.4 [8.4,8.5]

21,422

5.2 [5.1,5.3]

Constipation

35,832

6.4 [6.4,6.5]

16,729

4.0 [4.0,4.1]

Noninfectious gastroenteritis and colitis

29,602

5.3 [5.3,5.4]

12,837

3.1 [3.1,3.2]

Esophagitis

28,092

5.0 [5.0,5.1]

11,968

2.9 [2.8,2.9]

Nausea Alone

22,673

4.1 [4.0,4.1]

9,962

2.4 [2.4,2.5]

Malignant neoplasm of digestive organs and peritoneum

18,107

3.3 [3.2,3.3]

5,534

1.3 [1.3,1.4]

Flatulence, eructation and gas pain

17,263

3.1 [3.1,3.1]

7,209

1.7 [1.7,1.8]

Peptic ulcer diseases

13,914

2.5 [2.5,2.5]

6,311

1.5 [1.5,1.6]

Any GI-related hospitalization

121,189

21.8 [21.6,21.9]

55,744

13.5 [13.4,13.6]

  1. AF atrial fibrillation, GI gastrointestinal.
  2. aIncluding GI events observed during the 180-day baseline or study follow-up period.
  3. bThe 95% confidence intervals of GI events were computed using the binomial distribution.
  4. cIncluding GI events observed only during the study follow-up period (i.e., patients with history of GI at baseline were excluded).
  5. dIncluding dyspepsia, diarrhea, vomiting, and gastrointestinal bleeding.
  6. eDefined as abdominal pain upper, abdominal pain, abdominal discomfort, and dyspepsia.